Clinical Education

SMITHFIELD, R.I. – November 03, 2026 -- Acclaro Medical will showcase UltraClear, which it describes as the world's first 2910 nm cold ablative fiber laser, at the American Society for Dermatologic Surgery (ASDS) Annual Meeting, held November 4-8 in San Diego, California.

The company is using the conference to promote UltraClear as the anchor of a new skin resurfacing category. The platform covers treatments from prejuvenation and superficial resurfacing to advanced procedures, including treatment of excess skin with the proprietary Laser-Coring technique. Acclaro says the fiber laser is designed for all skin types, with faster healing and greater patient comfort.

Acclaro pitches the system as a single adaptable platform. Physicians can adjust treatments by skin concern, skin type, treatment depth and aesthetic objective. Indications cited include skin aging, pigmentation, scars and the effects of gravity.

Shanghai – October 30, 2026 -- aphranel®, the regenerative aesthetics brand of MOYOM Biotech, has brought European physicians to China for a week-long clinical exchange, following NMPA Class III approval for its MagiCCrystal CaHA filler in China in 2025 and EU MDR certification in 2026.

Delegation visits seven clinics across four Chinese cities

Dr. Tiago Guimarães and the aphranel® European Medical and Sales Team toured facilities with aphranel®-certified Chinese physicians. Stops included Yestar Medical Aesthetic Hospital and Huamei Zixin Medical Aesthetic Hospital in Guangzhou, and Shenzhen Fanyan Aesthetics and Shenzhen Boai Shuguang Hospital in Shenzhen. The group also visited REAL Medical Aesthetics in Shanghai, and Estee Ryan and JollyHue in Hangzhou.

The programme runs under the banner "Learning in China, Applying in Europe" and forms part of The Norns' Weave, a global academic initiative for physicians.

Gothenburg – October 22, 2026 -- The American College of Chest Physicians (CHEST) now runs more than 15 Surgical Science simulators across its training center and annual meeting, as the two organizations mark 10 years of partnership.

The anniversary will be celebrated at the CHEST 2026 Annual Meeting in Phoenix and year-round at the CHEST Simulation and Training Facility in Glenview, Illinois. CHEST serves more than 18,000 members worldwide in pulmonary, critical care and sleep medicine.

Co-developed BRONCH Express brings portable bronchoscopy training

The partners co-developed the BRONCH Express, a portable table-top simulator built for hands-on bronchoscopy skills and procedures. It extends training beyond the fixed installations at the Glenview center and the annual event.

Toronto – October 12, 2026 -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) has signed a co-education agreement with Telix Pharmaceuticals Limited (ASX:TLX; NASDAQ:TLX), giving it wider access to urologists in the U.S. and internationally through a strategic partner in prostate cancer imaging.

The agreement sets a framework to educate urologists, radiologists, nuclear medicine physicians and prostate cancer centers on how Telix's PSMA-targeting PET imaging agents, Gozellix and Illuccix, complement Profound's MRI-guided TULSA-PRO platform. The companies plan to cover the full prostate care continuum.

Budapest – September 22, 2026 -- South Korean biopharmaceutical company PharmaResearch officially launched its REJURAN portfolio of polynucleotide (PN)-based skin boosters in Hungary, marking its latest expansion move in Europe's aesthetic medicine market.

Symposium at Budapest museum draws 100 aesthetic medicine professionals

The launch event was held on September 14 at the Museum of Fine Arts, Budapest, marking REJURAN's first collaboration with the institution. Approximately 100 dermatologists, plastic surgeons and other aesthetic medicine specialists attended the symposium, which featured seven speakers from Korea, the Czech Republic, Slovakia and Hungary, including Korean key opinion leaders Dr. Hyun Jun Park and Dr. Kyu Ho Lee.